JB Pharma Reports 22% Profit Increase and 11% Revenue Growth in Q3 FY26

JB Chemicals Pharmaceuticals reported a 22% year-on-year rise in net profit to Rs 198 crore for Q3 FY26, supported by a favorable product mix and operational efficiencies. Revenue increased 11% to Rs 1,065 crore, driven by 10% growth in domestic formulations and 12% growth in international markets including South Africa, Russia, and the US. The contract drug manufacturing segment remained stable. CEO Nikhil Chopra highlighted focus on chronic therapies, flagship brands, and scaling CDMO businesses for sustained growth.